ArticleBMC psychiatry2021
Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report.
Article in BMC psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials.Frontiers in neurology · 2025Pooled it
- Efficacy of acupuncture for generalized anxiety disorder: A PRISMA-compliant systematic review and meta-analysis.Medicine · 2022Pooled it
- A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder.Psychiatry and clinical neurosciences · 2025Trial
- An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Patterns and predictors of the transition between minimally adequate treatment and effective treatment coverage for mental disorders: results from the World Mental Health Survey.International journal of mental health systems · 2026Article
- Anxiolytic Medication Use in Low- Middle- and High-Income Countries: A World Mental Health Surveys Report.Human psychopharmacology · 2026Article
- Anxiety, depression and perseverative cognition in women cycling naturally or taking oral contraceptives - a diary study.BMC psychology · 2025Article
- Feed, Read, and Grow: An Observational Study on the Impact of Educational Videos About Pediatric Anxiety.Cureus · 2025Article
- Mental health service coverage and gaps among adults in Europe: a systematic review.The Lancet regional health. Europe · 2025Review
- Effective Treatment for Mental and Substance Use Disorders in 21 Countries.JAMA psychiatry · 2025Article
- Intolerance of Uncertainty and Emotion Dysregulation as Predictors of Generalized Anxiety Disorder Severity in a Clinical Population.Journal of clinical medicine · 2025Article
- Psychometric properties of the Arabic generalized anxiety disorder scale (GAD-5) in a non-clinical sample of Arabic-speaking adults.Frontiers in psychology · 2025Article
- Differences in anxiety, worry, and perceived stress among naturally cycling women and oral contraceptives users: a cross-sectional study investigating the role of contraceptive types.Archives of women's mental health · 2024Article
- Diagnosis and Treatment of Generalized Anxiety Disorder in Japan: Psychiatric Specialist Survey.Neuropsychiatric disease and treatment · 2024Article
- Prevalence of Generalized Anxiety Disorder in Japan: A General Population Survey.Neuropsychiatric disease and treatment · 2024Article
- Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine.Neurology and therapy · 2023Article
- Mental Health of Parents and Their Children: A Longitudinal Study of the Effects of Parents' Negative Affect on Adolescents' Pathological Gaming.Healthcare (Basel, Switzerland) · 2022Article
- Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2022Article
- Measurement invariance of the GAD-5 Generalized Anxiety Disorder Scale in a Mexican general population sample.Frontiers in psychiatry · 2022Article
- How Do You TreatMedical acupuncture · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 23 countries.
Funding
Abstract
backgroundTreatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment.
methodsData came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment.
resultsThe overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness.
conclusionsThe majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.